Valeant Pharma (VRX) to Employ Drug Discounting Strategy in Effort to 'Protect Volume'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
UPDATE: Eventually Valeant (VRX) Fundamentals Will Matter Again - UBS
November 11, 2015 9:44 AM EST(Updated - November 11, 2015 9:49 AM EST)
(correction: price target is $255)
UBS analyst Marc Goodman reiterated a Buy rating and $255 price target on Valeant Pharmaceuticals (NYSE: VRX) following yesterday's business update. The analyst said eventually fundamentals will matter again. Goodman listed 6 takeaways from... More
Valeant (VRX) 'Conservative Base Case' Suggests 109% Upside - Nomura
November 11, 2015 7:20 AM ESTNomura Securities analyst Shibani Malhotra lowered her price target on Valeant Pharmaceuticals (NYSE: VRX) to $175.00 (from $220.00) but reiterated a Buy rating as her "Conservative Base Case" suggest 109% upside to current levels.
While the call did not address all our outstanding questions; however,... More
JPMorgan Cuts PT on Valeant (VRX) to $225
November 11, 2015 6:42 AM ESTJPMorgan trims its price target on Valeant Pharma (NYSE: VRX) from $265 down to $225. The firm maintained its Overweight rating on Valeant
For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.
... MorePhilidor Rx Disappointed Relationship with Valeant (VRX) Has Ended
November 10, 2015 5:22 PM ESTPhilidor Rx said in a statement:
We have valued our close working relationship with Valeant (NYSE: VRX) and are deeply disappointed that is has come to an end. It is unfortunate that this outcome was influenced by market forces, media misperceptions, and inflammatory,... More
Valeant Pharma (VRX) CEO Pearson Says Company 'is Going to Survive'
November 10, 2015 9:25 AM ESTWith its conference call today, Valeant Pharma (NYSE: VRX) said it doesn't have contingency plans if the stock keeps falling and it will sustain a short-term hit in its dermatology business.
CEO Michael Pearson also the company "is going to survive" and... More
UPDATE: Valeant Pharma (VRX) Sees Negative Q4 Impact from Recent Events; Will Issue New Guidance in Dec.
November 10, 2015 8:08 AM EST(Updated - November 10, 2015 8:23 AM EST)
(Updated - November 10, 2015 8:17 AM EST)
Valeant Pharma (NYSE: VRX) sees negative impact on dermatology in Q4, according to the company's... More
